Prohost Biotech
HomeArticlesNews & CommentsHarmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
News & Comments

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Harmony Biosciences Epilepsy News and the Treatment of Dravet Syndrome   Harmony Biosciences Holdings, Inc. (HRMY), announced that it will highlight new open-label extension data from the company’s in...
P

Prohost Biotech

4 min read
33
0

Harmony Biosciences Epilepsy News and the Treatment of Dravet Syndrome  

Harmony Biosciences Holdings, Inc. (HRMY), announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. The ARGUS trial is currently enrolling, and more information can be found at argustrial.com. The posters will be on display on Monday, December 8, from 8:00 am - 2:00 pm ET. Poster presentation details are listed below:
Abstract Title: EPX-100 as Adjunctive Therapy in Patients With Dravet Syndrome: Preliminary Results From the Open-Label Extension Phase of the ARGUS Study
Poster #: 3.353
Presentation: Monday, December 8, from 12:00 pm – 1:45 pm ET
Abstract Title: A Drug-Drug Interaction Study of EPX-100 (Clemizole Hydrochloride) With Clinical Probe Substrates for Selected CYP Enzymes
Poster #: 3.359
Presentation: Monday, December 8, from 12:00 pm – 1:45 pm ET

About Clemizole Hydrochloride (EPX-100)

EPX-100, clemizole hydrochloride, is an investigational product under development for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). EPX-100 acts by targeting central 5-hydroxytryptamine 2 (5HT-2) receptors to modulate serotonin signaling. EPX-100 is administered orally twice a day in a liquid formulation and has been developed based on a proprietary phenotype-based zebrafish drug screening platform. These scn1Lab mutant zebrafish replicate the genetic etiology and phenotype observed in the majority of individuals with DS. The scn1Lab mutant zebrafish model that expresses voltage gated sodium channels has been used for high-throughput screening of compounds that modulate Nav1.1 in the central nervous system.

About Dravet Syndrome

DS is a severe and progressive developmental epileptic encephalopathy that causes significant impact on patient functioning. DS begins in the first year of life and is characterized by high seizure frequency and severity, intellectual disability, and an increased risk of sudden unexpected death in epilepsy (SUDEP). Approximately 85% of Dravet syndrome cases are caused by de novo loss-of-function (LOF) mutations in a voltage-gated sodium channel gene, SCN1A. DS has an estimated incidence rate of 1:15,700 in the US. 

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com. Source version On businesswire.com:
https://www.businesswire.com/news/home/20251202699766/en/
Harmony Biosciences Investor Contact:  Matthew Beck 917-415-1750  [email protected] Harmony Biosciences Media Contact: Cate McCanless 202-641-6086 [email protected]Source: Harmony Source Biosciences Holdings, Inc.

Prohost Observations

It is important for physicians, Epileptic patients, their parents, and families to attend the 2025 American Epilepsy Society (AES) Annual Meeting that’s held on December 5 – December 9, 2025, in Atlanta, GA.  Needless to say that some kinds of epilepsy are extremely devastating and difficult to treat.

Tags

Harmony Biosciences (HRMY)

Comments (0)

Please sign in to join the discussion

Related Articles

News & Comments

Sentynl Therapeutics Inc Announces FDA Approval of ZYCUBO® for Menkes Disease in Pediatric Patients 

Sentynl Therapeutics JANUARY 13, 2026, Sentynl Therapeutics – a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited (“Zydus Group”), announced that the U.S. FDA has approv...
P

Prohost Biotech

Jan 13, 2026

9m
38
News & Comments

Eli Lilly Lowers the Price of Zepbound® (tirzepatide) Single-Dose Vials

Lilly in the NEWS INDIANAPOLIS, December 1, 2025, Eli Lilly and Company (LLY) today announced Zepbound® (tirzepatide) single-dose vials will now be available at lower prices on LillyDirect, the compan...
P

Prohost Biotech

Dec 1, 2025

6m
33
News & Comments

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs, Including Parkinson's Disease

Aspen Neuroscience Aspen Neuroscience, Inc. - a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced the closing of a $115 million Series C financing round. Thi...
P

Prohost Biotech

Nov 21, 2025

5m
41